Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein

Dengue virus (DENV) infection imposes enormous health and economic burden worldwide with no approved treatment. Several small molecules, including lovastatin, celgosivir, balapiravir and chloroquine have been tested for potential anti-dengue activity in clinical trials; none of these have demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Budigi, Yadunanda, Ong, Eugenia Z., Robinson, Luke N., Ong, Li Ching, Rowley, Kirk J., Winnett, Alexander, Tan, Hwee Cheng, Hobbie, Sven, Shriver, Zachary, Babcock, Gregory J., Alonso, Sylvie, Ooi, Eng Eong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823465/
https://www.ncbi.nlm.nih.gov/pubmed/29425203
http://dx.doi.org/10.1371/journal.pntd.0006209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823465/
https://www.ncbi.nlm.nih.gov/pubmed/29425203
http://dx.doi.org/10.1371/journal.pntd.0006209

Ejemplares similares